POMDOCTOR LIMITED (Class A) (POM) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, POMDOCTOR LIMITED (Class A) (NASDAQ: POM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.54 (-22.61% 1D, market cap $5.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1011 tracked Consumer Discretionary issuers, POM ranks #794 in composite RQD confidence.
Within the Consumer Discretionary sector (Other Specialty Stores), POM carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 13.1%, and ROIC of -35.0%. By comparison, YJ (Yunji Inc. American Depository Shares) holds a E grade (30/100 RQD, P/E N/A, ROIC -13.7%, cap $6.1M) and BQ (Boqii Holding Limited (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC —, cap $3.9M). Among the 5-stock peer group, TKLF leads on earnings multiple (11.9x) while YJ leads on capital efficiency (-13.7% ROIC).
Per POM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001877971), POMDOCTOR LIMITED (Class A) generated $57.2M in revenue, $0 in net income, and -$21.4M in free cash flow against $15.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
20D Institutional Volume Accumulation (±12.5% realized swing band)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While POM currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Consumer Discretionary with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.00) and Max Pain ($1.62) forces dealer call-delta covering toward $121.53.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
POMDOCTOR LIMITED (Class A) (POM) dropped -22.61% to $1.54, trading at 2% of its 52-week range ($0.43 – $115.74). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
Oct. 30, 2026 US top movers: CHOW rose 137.0% to lead gainers, while JDZG fell 57.8% to lead losers. See the session's sharpest percentage swings.
Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor Therapeutics
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on POM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for POM. Explore sector supply chains on /butterfly.
Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, POMDOCTOR LIMITED (Class A) (POM) ranks #794 by composite RQD confidence (37/100, grade D-) and #964 by equity capitalization ($5.5M). Within this direct 5-issuer industry benchmark cohort, TKLF leads on earnings valuation at 11.9x trailing P/E, while YJ leads on capital efficiency and profitability with -13.7% ROIC and 44.4% gross margin. TKLF currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with POM at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| POM
ACTIVE
POMDOCTOR LIMITED (Class A) | D- | 37/100 | — | 13.1% | -35.0% | -22.61% | $5.5M | Benchmark Subject |
| YJ Yunji Inc. American Depository Shares | E | 30/100 | — | 44.4% | -13.7% | -3.25% | $6.1M | /yj-vs-pom → |
| BQ Boqii Holding Limited (Class A) | E | 34/100 | — | 26.3% | — | -3.29% | $3.9M | /bq-vs-pom → |
| TKLF Tokyo Lifestyle Co. Ltd. | D- | 40/100 | 11.9x | — | — | -1.96% | $8.5M | /tklf-vs-pom → |
| WBUY WEBUY GLOBAL LTD. (Class A) | E | 24/100 | — | 12.0% | -35.0% | -10.49% | $3.3M | /wbuy-vs-pom → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), POMDOCTOR LIMITED (Class A) (POM) reported GAAP revenue of $57.2M , GAAP net income of $0, operating cash flow of -$21.2M, and free cash flow of -$21.4M . On the balance sheet, POM closed FY2025 with $15.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $57.2M | $0 | -$21.2M | -$21.4M | $15.4M | — |
As of 2026-11-02, POMDOCTOR LIMITED (Class A) (NASDAQ: POM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.54 (-22.61% 1D, market cap $5.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1011 tracked Consumer Discretionary issuers, POM ranks #794 in composite RQD confidence.
Within the Consumer Discretionary sector (Other Specialty Stores), POM carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 13.1%, and ROIC of -35.0%. By comparison, YJ (Yunji Inc. American Depository Shares) holds a E grade (30/100 RQD, P/E N/A, ROIC -13.7%, cap $6.1M) and BQ (Boqii Holding Limited (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC —, cap $3.9M). Among the 5-stock peer group, TKLF leads on earnings multiple (11.9x) while YJ leads on capital efficiency (-13.7% ROIC).
Per POM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001877971), POMDOCTOR LIMITED (Class A) generated $57.2M in revenue, $0 in net income, and -$21.4M in free cash flow against $15.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
POM last traded at $1.54 (-22.61% on volume of 723,684 shares), positioning the stock +54.00% above its 50-day simple moving average ($1.00) and -47.08% below its 200-day simple moving average ($2.91). Across its 52-week range of $0.43 to $115.74, POM sits at the 1.0% percentile with a 14-day RSI of 58.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.35 to $1.73).
Why POM Stock dropped -22.61% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, POM scores 37 out of 100 with a letter grade of D- and a verdict of "Roarable Sell — Vulnerable Balance Sheet & Flow." The fundamental cash engine pillar scores 5 of 20, reflecting ROIC of -35% and an FCF yield of 0%, which indicates the business is not currently generating returns on invested capital or free cash flow relative to its valuation. The whale 13F flow pillar scores 9 of 20 for institutional accumulation and options positioning, which is the second-weakest reading and suggests limited sponsorship from large holders. The insider conviction pillar scores 5 of 20 based on SEC Form 4 and Congressional PTR cluster flow, indicating weak insider signaling. The macro regime fit pillar scores 8 of 20 with a beta of 1.0 and sector sensitivity considered. The forensic balance sheet pillar scores 10 of 20, with an Altman Z-Score of 2.5, a Piotroski F-Score of 1/9, and Debt/Equity of 0.5. For a prospective investor, the upside case rests on any turnaround in cash generation, which the rating does not show yet; the valuation tradeoff is that the price of $1.99 is set against negative operating margin and zero net margin, leaving little earnings support; and the rating's weakest links (cash engine, insider conviction, and whale flow) are the signals that would need to improve before the thesis strengthens.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $57.2M | $-17.0M | $0.0M | N/A | $-21.4M | $1.4M | N/A |
Per the SEC financials, FY 2025 (filed 2025-12-31) shows operating income of $-17.0M and free cash flow of $-21.4M, with net income at $0.0M. Per market data, gross margin is 13.1%, operating margin -29.7%, and net margin 0%, with ROIC of -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. Cash of $1.4M is small relative to the negative free cash flow reported for the period.
Per the recent news feed, the dominant items are corporate and listing-related: announcements of termination of the ADR program with Class A shares trading on Nasdaq, receipt of a Nasdaq Staff Delisting Determination, and a 10-for-1 share consolidation. Each is flagged YELLOW. Market-action items note a pullback amid volatility and a 15.88% decline to $0.53 with a $0.50 support level referenced. Risk watch items are the delisting determination and the share consolidation. The Butterfly supply-chain graph reports sector Consumer Discretionary, industry Other Specialty Stores, supply chain "NONE," with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for POMDOCTOR LIMITED (Class A) (POM) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering POMDOCTOR LIMITED (Class A) (POM) market action, institutional positioning, and fundamental catalysts.
Welcome to the POM (POMDOCTOR LIMITED (Class A)) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Other Specialty Stores. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on POM, but look at what you are paying: current EV/EBITDA multiples with 13.1% gross margins. Unless POMDOCTOR LIMITED (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on POM, the market is fixating on short-term headline noise in Other Specialty Stores and ignoring the balance sheet and cash flow trajectory. At $1.99 (52-wk range $0.43 - $115.74), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).